Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03632993 · ClinicalTrials.gov registry record · Phase 2
Injection Techniques of Collagenase Clostridium Histolyticum (CCH) for the Treatment of EFP (Cellulite)
A Phase 2 study, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 64
- Enrollment target
NCT03632993: Completed Phase 2 study, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
NCT03632993 is a Phase 2 study that has completed, run by Endo USA Inc., a Keenova Therapeutics Company. The registered enrollment target is 64 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03632993, a Phase 2 study, has completed, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 64 participants
- Enrollment target
Study Summary
The study will evaluate the safety and effectiveness of different injection techniques of Collagenase Clostridium Histolyticum (CCH) for the treatment of adult women with mild, moderate or severe Edematous Fibrosclerotic Panniculopathy (commonly known as Cellulite).
Interventions
- DRUG collagenase clostridium histolyticum (CCH)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2018-09-18 |
| Est. Completion | 2019-01-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03632993
The ClinicalTrials.gov registry entry for NCT03632993 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Endo USA Inc., a Keenova Therapeutics Company, which has 61 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which collagenase clostridium histolyticum (CCH) is the first listed.
NCT03632993 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03632993 about?
NCT03632993 is a clinical study titled "Injection Techniques of Collagenase Clostridium Histolyticum (CCH) for the Treatment of EFP (Cellulite)". The study will evaluate the safety and effectiveness of different injection techniques of Collagenase Clostridium Histolyticum (CCH) for the treatment of adult women with mild, moderate or severe Edematous Fibrosclerotic Panniculopathy (commonly known as Cellulite).
What is the current status of trial NCT03632993?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2018-09-18. Estimated completion is 2019-01-24.
What interventions are being tested in trial NCT03632993?
The interventions under investigation include: collagenase clostridium histolyticum (CCH) (DRUG).
Who is sponsoring clinical trial NCT03632993?
This trial is sponsored by Endo USA Inc., a Keenova Therapeutics Company, which has 61 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.